XML 48 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Account Detail (Tables)
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Cash and Cash Equivalents and Marketable Securities
The following is a summary of our presented composition of “cash and cash equivalents” and “marketable securities”:
Historical or Amortized CostFair ValueCash and Cash
Equivalents		Marketable Securities
December 31, 2022
Money market funds$36,298 $36,298 $36,298 $— 
Equity securities(1)
— 136 — 136 
Government-related debt securities30,359 30,348 — 30,348 
Mutual funds 3,395 4,244 — 4,244 
Bank deposits4,070 4,070 4,070 — 
Total cash and cash equivalents and marketable securities$74,122 $75,096 $40,368 $34,728 
December 31, 2021
Money market funds$66,322 $66,322 $66,322 $— 
Equity securities3,512 5,718 — 5,718 
Mutual funds5,218 6,390 — 6,390 
Bank deposits22,217 22,217 22,217 — 
Total cash and cash equivalents and marketable securities$97,269 $100,647 $88,539 $12,108 
 (1)Our aggregate equity holdings consist of 0.3 million common shares of Unicycive Therapeutics, Inc., a NASDAQ-listed biopharmaceutical company, with a fair market value of $0.1 million as of December 31, 2022. We completed the sale of 0.6 million shares of common stock and recognized a $0.5 million gain within “other expense, net” within the accompanying Consolidated Statements of Operations for the year ended December 31, 2022. Additionally, we completed the sale of our remaining 0.9 million shares of CASI Pharmaceuticals, Inc., a NASDAQ-listed biopharmaceutical company, and recognized a $1.9 million loss within “other expense, net” within the accompanying Consolidated Statements of Operations for the year ended December 31, 2022. We no longer hold any shares of CASI Pharmaceuticals, Inc.
Schedule of Inventories
Upon approval of ROLVEDON on September 9, 2022, we began capitalizing our purchases of saleable inventory of ROLVEDON from suppliers. Inventories consist of the following:
December 31,
20222021
Raw materials$4,500 $— 
Work-in-process4,007 — 
Finished goods723 — 
Inventories$9,230 $— 
Schedule of Accounts Payable and Other Accrued Liabilities “Accounts payable and other accrued liabilities” consists of the following, with “Product revenue allowances – ROLVEDON” being as of and for the year ended December 31, 2022:
 December 31,
 20222021
Trade accounts payable and other$30,547 $33,408 
Lease liability - current portion761 1,282 
Product revenue allowances - ROLVEDON3,082 — 
Commercial Product Portfolio accruals (Note 10)3,715 6,568 
Accounts payable and other accrued liabilities$38,105 $41,258 
Schedule of Amounts Presented in Accounts Payable and Other Accrued Liabilities Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Consolidated Balance Sheets for our categories of gross-to-net (“GTN”) estimates related to discontinued operations (Commercial Product Portfolio) accruals were as follows:
Commercial/Medicaid Rebates and Government ChargebacksDistribution,
Data, Inventory, and
GPO Administrative
Fees		Product Return AllowancesTotal
Balance as of December 31, 2020$2,601 $942 $4,299 $7,842 
(Less): Payments and credits against GTN accruals(1,159)— (115)(1,274)
Balance as of December 31, 20211,442 942 4,184 6,568 
(Less): Payment and credits against GTN accruals(5)93 (203)(115)
(Less): Release of GTN accruals(117)(871)(1,750)(2,738)
Balance as of December 31, 2022$1,320 $164 $2,231 $3,715